What happened
Celltrion Pharm filed provisional (unaudited) separate results for Q2 2026: revenue of US$107M (+16.75% year on year), operating profit of US$13.5M (+24.37% year on year) and net income of US$9.61M (+23.74% year on year).
These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.
| Revenue | US$107M |
|---|---|
| Revenue vs a year earlier | +16.75% |
| Operating profit | US$13.5M |
| Net income | US$9.61M |
| Period | Q2 2026 (separate) |
| Filed | 2026-08-04, Operating results (preliminary) (fair disclosure) |
| Source | DART rcept 20260804900438 → open original filing |
Source: DART. Information only, not investment advice.